Sorafenib versus Transarterial chemoembolization for advanced-stage hepatocellular carcinoma: a cost-effectiveness analysis.
about
Sorafenib versus Transarterial chemoembolization for advanced-stage hepatocellular carcinoma: a cost-effectiveness analysis.
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh-hant
name
Sorafenib versus Transarterial ...... a cost-effectiveness analysis.
@en
Sorafenib versus Transarterial ...... a cost-effectiveness analysis.
@nl
type
label
Sorafenib versus Transarterial ...... a cost-effectiveness analysis.
@en
Sorafenib versus Transarterial ...... a cost-effectiveness analysis.
@nl
prefLabel
Sorafenib versus Transarterial ...... a cost-effectiveness analysis.
@en
Sorafenib versus Transarterial ...... a cost-effectiveness analysis.
@nl
P2093
P2860
P1433
P1476
Sorafenib versus Transarterial ...... a cost-effectiveness analysis.
@en
P2093
Haibo Wang
Hanmei Zhang
Mengchao Wei
Ming Kuang
Mingfong Cheong
Shuling Chen
Weifeng Liu
Zhenwei Peng
P2860
P2888
P356
10.1186/S12885-018-4308-7
P407
P577
2018-04-05T00:00:00Z
P6179
1103128621